ROUNDTABLE How does Genome Editing Advance the Field?
Thursday, June 1, 2023 03:45 PM - 04:45 PM
Salle Maillot
Clinic & the Lab
Roundtable
Debate advantages and disadvantages of the two dominant gene-editing technologies. Is one better than the other?
Moderator
Shirley Bartido, PhD, MBA, Director, Global Regulatory Affairs Cell Therapy Oncology, Takeda Pharmaceutical Company Limited, USA
Panelists
Shengdar Tsai, PhD, Associate Member, St. Jude Children's Research Hospital, USA
Mo Heidaran, PhD, Head of Regulatory and Translational Strategy, GC Therapeutics, USA
Stephan Reynier, MSc, Chief Regulatory and Compliance Officer, Cellectis SA, France
Learning Objectives
Moderator
Shirley Bartido, PhD, MBA, Director, Global Regulatory Affairs Cell Therapy Oncology, Takeda Pharmaceutical Company Limited, USA
Panelists
Shengdar Tsai, PhD, Associate Member, St. Jude Children's Research Hospital, USA
Mo Heidaran, PhD, Head of Regulatory and Translational Strategy, GC Therapeutics, USA
Stephan Reynier, MSc, Chief Regulatory and Compliance Officer, Cellectis SA, France
Learning Objectives
- Describe the principles of rational design by which novel tools for genetic modification can be made more precise.
- Discuss methods and techniques for detection of off target genetic modification to make genetically modified cellular products safer.
- Discuss regulatory guidelines promoted for the safe and efficacious utilization of genome-editing technologies
Shirley Bartido PhD, MBA
Director, Global Regulatory Affairs Cell Therapy Oncology
Takeda Pharmaceutical Company Limited
Moderator
Director, Global Regulatory Affairs Cell Therapy Oncology
Takeda Pharmaceutical Company Limited
Moderator
